ATHE

Alterity Therapeutics Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website alteritytherapeutics.com
Employees(FY) 11
ISIN US02155X2053

Performance

-0.9%

+96.43%

+81.82%

+17.65%

-11.65%

YTD

-17.3%

Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Advanced Technical Analysis

Technical Analysis of ATHE 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 43 suggests a neutral stance that may warrant caution. Overall, the Technical Score of 66 reinforces a generally positive outlook, though investors should remain mindful of potential fluctuations indi...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ATHE

Stock Rank

Recent News & Updates

2024-12-03 18:35
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy(Globenewswire)
2024-11-18 18:25
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary(Globenewswire)
2024-11-11 18:35
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium(Globenewswire)
2024-11-05 18:35
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434(Globenewswire)
2024-10-30 19:35
Appendix 4C Q1 FY25 Quarterly Cash Flow Report(Globenewswire)
2024-10-13 19:35
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024(Globenewswire)
2024-10-10 19:35
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting(Globenewswire)
2024-10-01 19:35
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders(Globenewswire)
2024-09-29 19:35
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer(Globenewswire)
2024-09-22 19:35
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders(Globenewswire)
2024-07-30 19:35
Appendix 4C Q4 FY24 Quarterly Cash Flow Report(Globenewswire)
2024-07-23 19:35
Alterity Therapeutics to Present at MST Financial Webinar(Globenewswire)
2024-07-17 23:01
Alterity (ATHE) Up on Interim Data From Advance MSA Study(Yahoo Finance)
2024-07-16 19:35
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy(Globenewswire)
2024-06-12 07:22
Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar(Globenewswire)
2024-05-29 07:21
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study(Globenewswire)
2024-05-07 19:25
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review(Globenewswire)
2024-04-29 19:25
Appendix 4C Q3 FY24 Quarterly Cash Flow Report(Globenewswire)
2024-04-28 19:25
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia(Globenewswire)
2024-04-16 19:25
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting(Globenewswire)
2024-04-09 19:25
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024(Globenewswire)
2024-03-25 22:25
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund(Globenewswire)
2024-02-19 21:25
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting(Globenewswire)
2024-02-05 18:25
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review(Globenewswire)
2024-01-28 18:24
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week(Globenewswire)
2024-01-21 18:25
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones(Globenewswire)
2023-12-20 11:30
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer(Globenewswire)
2023-12-04 03:35
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress(Globenewswire)
2023-12-04 01:15
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?(Investorplace)
2023-12-03 18:25
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.